CA2448483A1 - Compositions et procedes permettant de traiter la reponse cellulaire aux lesions et d'autres troubles de la proliferation cellulaire regules par les hyaladherines et les hyaluronanes - Google Patents

Compositions et procedes permettant de traiter la reponse cellulaire aux lesions et d'autres troubles de la proliferation cellulaire regules par les hyaladherines et les hyaluronanes Download PDF

Info

Publication number
CA2448483A1
CA2448483A1 CA002448483A CA2448483A CA2448483A1 CA 2448483 A1 CA2448483 A1 CA 2448483A1 CA 002448483 A CA002448483 A CA 002448483A CA 2448483 A CA2448483 A CA 2448483A CA 2448483 A1 CA2448483 A1 CA 2448483A1
Authority
CA
Canada
Prior art keywords
rhamm
cells
antibody
binds
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002448483A
Other languages
English (en)
Inventor
Eva A. Turley
Tony F. Cruz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Transition Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transition Therapeutics Inc filed Critical Transition Therapeutics Inc
Publication of CA2448483A1 publication Critical patent/CA2448483A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La présente invention concerne des compositions et des procédés permettant de traiter un trouble tissulaire associé à un processus de réponse à une lésion ou à des cellules prolifératrices chez un mammifère. Ces troubles tissulaires sont associés à un nouveau phénotype cellulaire désigné par le terme "cellules de transition", qui est décrit ci-après. Ce phénotype cellulaire est caractérisé par une activité de signalisation erk kinase activée, une activité de liaison AP-1 stimulée, et au moins une caractéristique choisie dans le groupe composé de: (a) une formation de podosomes augmentée; (b) un flux augmenté de hyaluronanes ou de hyaladhérines intracellulaires ou extracellulaires, (c) une expression augmentée d'une hyaladhérine; (d) une incapacité à former des adhésions focales; (e) une activité métalloprotéinase augmentée; et (f) une expression augmentée d'une hyaladhérine. Des exemples de troubles tissulaires comprennent la fibrose, l'inflammation, la dégénérescence et les troubles invasifs tels que ceux qui se produisent dans les cellules cancéreuses. Les procédés de l'invention consistent à administrer au mammifère une quantité efficace d'une composition qui modifie l'activité des molécules de transition à l'intérieur d'une cellule. Les molécules de transition sont composées des hyaladhérines, des hyaluronanes et de molécules associées qui régulent le phénotype de transition. L'invention se rapporte également à une nouvelle culture cellulaire comprenant des cellules de transition, ainsi qu'à des compositions renfermant des peptides, des polypeptides et des anticorps particuliers qui modifient le phénotype de transition.
CA002448483A 2000-10-05 2000-10-05 Compositions et procedes permettant de traiter la reponse cellulaire aux lesions et d'autres troubles de la proliferation cellulaire regules par les hyaladherines et les hyaluronanes Abandoned CA2448483A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2000/001534 WO2002028415A1 (fr) 2000-10-05 2000-10-05 Compositions et procedes permettant de traiter la reponse cellulaire aux lesions et d'autres troubles de la proliferation cellulaire regules par les hyaladherines et les hyaluronanes

Publications (1)

Publication Number Publication Date
CA2448483A1 true CA2448483A1 (fr) 2002-04-11

Family

ID=11003988

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002448483A Abandoned CA2448483A1 (fr) 2000-10-05 2000-10-05 Compositions et procedes permettant de traiter la reponse cellulaire aux lesions et d'autres troubles de la proliferation cellulaire regules par les hyaladherines et les hyaluronanes

Country Status (4)

Country Link
EP (1) EP1324765A1 (fr)
AU (1) AU2000278122A1 (fr)
CA (1) CA2448483A1 (fr)
WO (1) WO2002028415A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1165112B1 (fr) * 1999-03-26 2006-06-07 The University Of Texas System Modulateurs de polysaccharides et leurs utilisations
US6911429B2 (en) * 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
CA2610791C (fr) 2005-06-08 2015-12-01 Cangene Corporation Peptides de liaison a l'acide hyaluronique pour ameliorer les defenses de l'organisme hote contre les bacteries pathogenes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207949D0 (en) * 1992-04-09 1992-05-27 Univ Manitoba Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility
GB9420740D0 (en) * 1994-10-14 1994-11-30 Univ Manitoba Sequence of the hyaluronan receptor gene
GB9607441D0 (en) * 1996-04-10 1996-06-12 Univ Manitoba Human hyaluronan receptor
CA2237051A1 (fr) * 1997-12-19 1999-06-19 Eva A. Turley Affinite amelioree de peptides lies a l'hyaluronan
EP1169048A4 (fr) * 1998-07-06 2002-07-17 Glenn D Prestwich Analogues d'acide hyaluronique et procedes correspondants
EP1151012A4 (fr) * 1998-11-19 2003-01-08 Smithkline Beecham Corp Anticorps antagonistes du rhamm

Also Published As

Publication number Publication date
WO2002028415A1 (fr) 2002-04-11
EP1324765A1 (fr) 2003-07-09
AU2000278122A1 (en) 2002-04-15

Similar Documents

Publication Publication Date Title
JP4722290B2 (ja) 結合組織成長因子（ｃｔｇｆ）断片とそれを用いた方法および使用
US6864235B1 (en) Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
JP6420459B2 (ja) 線維症抑制活性を有するペプチド及びこれを含む組成物
ES2397441T3 (es) Secuencias polinucleotídicas y polipeptídicas implicadas en el proceso de remodelación ósea
US20110009337A1 (en) Q3 sparc deletion mutant and uses thereof
JP2004504063A (ja) 新規線維芽細胞増殖因子（ｆｇｆ２３）および使用方法
JP2002523035A (ja) ４９個のヒト分泌タンパク質
JP2001509029A (ja) ヒトタンパク質
US6525018B1 (en) Treating eye disorders using intestinal trefoil proteins
JP2002533058A (ja) ９７個のヒト分泌タンパク質
JP2002506627A (ja) ９５個のヒト分泌タンパク質
JP2002506625A (ja) サイトカインレセプター共通γ鎖様
US6911429B2 (en) Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
JP2002526059A (ja) ３１個のヒト分泌タンパク質
JP2002530062A (ja) １２個のヒト分泌タンパク質
US20040167067A1 (en) ESM-1 gene differentially expressed in angiogenesis, antagonists thereof, and methods of using the same
US20050147602A1 (en) Compositions, methods and kits relating to CTHRC1, a novel modulator of collagen matrix
KR20110117982A (ko) Ｎｆａｔ５ 억제제를 유효성분으로 함유하는 혈관형성 관련 질환의 예방 또는 치료용 조성물
JP2002505871A (ja) ３１個のヒト分泌タンパク質
US6630325B1 (en) Compositions, methods and kits relating to remodel
CA2448483A1 (fr) Compositions et procedes permettant de traiter la reponse cellulaire aux lesions et d'autres troubles de la proliferation cellulaire regules par les hyaladherines et les hyaluronanes
JP2004508827A (ja) カルシウム結合タンパク質
AU2002333100A1 (en) Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
WO2006019193A1 (fr) Utilisation d'un inhibiteur et d'un promoteur
JP4344408B2 (ja) 新規タンパク質およびそのｄｎａ

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead